Protocol for data extraction: how real-world data have been used in the National Institute for Health and Care Excellence appraisals of cancer therapy

Jiyeon Kang, John Cairns

ABSTRACT

Introduction Due to the limitations of relying on randomised controlled trials, the potential benefits of real-world data (RWD) in enriching evidence for health technology assessment (HTA) are highlighted. Despite increased interest in RWD, there is limited systematic research investigating how RWD have been used in HTA. The main purpose of this protocol is to extract relevant data from National Institute for Health and Care Excellence (NICE) appraisals in a transparent and reproducible manner in order to determine how NICE has incorporated a broader range of evidence in the appraisal of oncology medicines.

Methods and analysis The appraisals issued between January 2011 and May 2021 are included following inclusion criteria. The data extraction tool newly developed for this research includes the critical components of economic evaluation. The information is extracted from identified appraisals in accordance with extraction rules. The data extraction tool will be validated by a second researcher independently. The extracted data will be analysed quantitatively to investigate to what extent RWD have been used in appraisals. This is the first protocol to enable data to be extracted comprehensively and systematically in order to review the use of RWD.

Ethics and dissemination This study is approved by the Ethics Committee of the London School of Hygiene and Tropical Medicine on 14 November 2019 (17315). Results will be published in peer-reviewed journals.

INTRODUCTION

In the last few years, interest in real-world data (RWD) has grown in healthcare decision-making. Health Technology Assessment (HTA) refers to the systematic evaluation of clinical-effectiveness and cost-effectiveness of health technology. Health technologies include drugs, medical devices, diagnostics, surgical procedures to mitigate health issues and improve the quality of life. HTA requires valid and reliable information to evaluate such technologies. Randomised controlled trials (RCTs) have mainly provided the information. However, it is challenging to meet all information needs from RCTs since the new generation of therapies poses several assessment challenges. For example, when treatment options are expanding rapidly, it is increasingly unlikely that there are RCTs featuring all of the relevant comparators. Furthermore, the traditional design of RCTs is possibly less appropriate for new technologies such as those targeting rare genetic mutations where it is harder to recruit patients from the clinically relevant populations. Moreover, RCTs often have strict inclusion criteria reducing generalisability. Another barrier to obtaining the information required for HTA from RCTs relates to the extrapolation of survival. Extrapolation is required in order to incorporate the survival data from RCTs in the health economic model. It is more challenging to identify the most appropriate extrapolation the shorter the duration of the trial. If survival data from RCTs are based on a very limited observation period,
the extrapolation of the survival curve is likely to fail to predict the long-term effect.\(^9\)

The potential benefits of RWD in enriching evidence for HTA are highlighted by the limitations of relying on RCTs.\(^{10}\) This research focuses on the use of RWD in HTA by the National Institute for Health and Care Excellence (NICE). NICE has achieved an international reputation for rigorous development and application of scientific methods to appraise new health technologies to provide its decisions with robust and fair justification.\(^{11}\) More importantly, NICE is noted for the transparency of its processes, responsiveness to change and commitment to using the best available evidence.\(^{12}\) The structure of the relevant documents facilitates identification of the key information and the documents are available on the NICE website. Therefore, review of these appraisals can provide comprehensive information on the evidence used for decision-making. In April 2020, NICE signalled its intention to integrate broader types of data in developing NICE guidance.\(^{13}\) Although it is primarily a statement of intent, it is not a new development in NICE practice since NICE already incorporates a diverse range of published scientific evidence when developing its guidance on health technologies. For example, UK audit data (TA255, 2012), Hospital Episode Statistics (TA559, 2018) and registry data such as the Edinburgh Ovarian Cancer Database (TA598, 2019), Surveillance, Epidemiology and End Result programme (TA562, 2019) have been used in the development of NICE technology appraisal (TA) guidance. While a wide range of data are already used in NICE guidance, there is limited understanding regarding how and where RWD have been used, and in which circumstances RWD are accepted as relevant. Research is required to investigate systematically patterns in the use of RWD and to understand the driving forces behind its use in NICE appraisals.

Several researchers have reviewed practice across HTA bodies\(^{14,15}\) or reported the use of RWD in HTA.\(^{16}\) However, little systematic research has been conducted. Important information is missing such as how they included literatures without selection bias, which parts of the evidence were reviewed, whether they have clearly defined RWD and justified or explained why this definition is relevant and how different HTA systems were compared given their different practices. Roberts et al addressed the potential role of RWD in bridging the evidence gaps.\(^{17}\) However, they illustrate the use of RWD with a few examples, rather than providing a fuller picture of current practice when using RWD. Bullement et al recently reviewed how RWD informed single TAs of cancer drugs in NICE.\(^{18}\) Although this study follows a more systematic approach to the review of the use of RWD, a data extraction table was not provided and the authors focused only on how real-world evidence (RWE) influenced the cost-effectiveness analysis, and not on how RWE was used to support or establish the appraisal. Due to limited information presented concerning the review process in this study, it is unclear whether the information presented provides a full picture of the use of RWD. Bullement et al included 113 single-technology appraisals (STAs) issued between April 2011 and October 2018. As interest in RWD is increasing over time, it may miss relevant information from recent years. This extraction protocol is required to help extract the data systematically from appraisals, to increase the reliability of the results of the analysis and to permit a more detailed description of the use of RWD and analysis of factors influencing its use.

A protocol is required to ensure the consistency of data extraction so that the risk of unsystematic data collection is reduced. The main purpose of this protocol is to extract data from NICE appraisals in a transparent and reproducible manner to answer, ‘how has NICE incorporated a broad range of evidence in the appraisal of oncology medicines?’. Without proper justification and operational rules, the data may not be extracted consistently, with a risk of biasing the analysis. The extracted data are expected to be objective and less biased. By cross-referencing these data, subsequent analysis can provide more robust answers to questions regarding how RWD have been used in NICE TAs. Furthermore, this protocol facilitates the development of a rich dataset which can highlight not just where RWD have been used but also what types of evidence have been used in the HTA process in line with NICE’s interest in incorporating a broad range of evidence. The data can be analysed to answer several research questions including ‘how has RWD been used in NICE appraisals?’ and ‘which factors are associated with increased likelihood of the use of RWD?’ in depth.

**METHODS AND ANALYSIS**

NICE appraisal documents are identified following inclusion criteria (figure 1). The information is extracted from identified appraisals in accordance with extraction

---

**Figure 1** Inclusion/exclusion criteria. STA, single-technology appraisal.
rules. The detailed extraction rules can be found in online supplemental file 1. The extraction tool includes evidence-related information such as characteristics of the main clinical evidence and the economic evaluation model and other information. Using this tool, information will be collected about which parts of the cost-effectiveness analyses used RWD. Analyses of the intensity of use of RWD and regression analyses are planned. The data analysis is expected to start from January 2022 and be completed by December 2022.

Definition of RWD

A definition of RWD is clearly required before extracting information about the use of RWD in NICE. RWD are umbrella terms which cover broad categories of data. Although RWD are increasingly addressed in the literature, there is no consensus over the definition. One of the commonly used definitions of RWD is that of the US Food and Drug Administration (FDA). Another widely cited study regarding the definition of RWD is Makady et al. Each definition has relatively large operational flexibility to be used for data extraction. For example, companies sometimes present phase 1 clinical trial as RWD. However, these data hardly provide insights in the discussion of the use of RWD in HTA. Requiring data to meet both definitions can help to reduce the discretionary interpretation of RWD. Hence, this study uses a definition combining a category of the study designs of collecting RWD explored by Makady et al’s study and the FDA’s definition of RWD focusing on routinely collected data. In this research, RWD are defined as the data relating to patient health status and/or the delivery of healthcare routinely collected from non-experimental settings.

Step 1: appraisal selection

The first step of the research identifies the NICE TA guidance which meets the eligibility criteria. TA guidance is publicly available on the NICE website (www.nice.org.uk). This study focuses on four types of appraisal documents, the final scope, the manufacturer’s submission, the evidence review group report and the final appraisal determination. These documents are reviewed to establish whether RWD are used to determine any components of the economic evaluation.

Data sources

This research exclusively includes STAs of oncology medicines. Figure 1 shows the inclusion and exclusion criteria. One aim is to understand how and where RWD have been used in the appraisal process. Therefore, it is necessary that the appraisal process should be identical. However, the STA and multiple technology appraisal (MTA) processes differ substantially. The MTA has different format of appraisal documents to assess several drugs or treatments used for one or more condition. It is challenging to gather the same information in the MTA process as different actors are responsible for producing and reviewing the main pieces of evidence.

Besides, STAs are the predominant form in practice, 93% of appraisals of oncology. The small number of the MTAs, only 18 oncology appraisals, limits the scope for a comparison of MTAs and STAs in terms of the use of RWD. Therefore, this study focuses on STAs, which assess a single treatment. It also limits analysis to appraisals published between January 2011 and May 2021 in order to have a long enough time period to capture potential changes over time in how RWD have been used but also recognising that STAs from earlier years might be of less interest because enthusiasm for RWD was largely absent. Here, the date when guidance was published refers to the date of issuing the final appraisal determination document (FAD) which can be regarded as an end point of the evidence synthesis process (in the absence of a successful appeal).

Operational separation

Following the inclusion and exclusion criteria, appraisals are identified. Among these appraisals, some TAs have more than one clinical indication or involve combination therapy. It is possible that different evidence was used for the different patient populations in the appraisal. Hence, these appraisals are separated by clinical conditions or treatment lines and reviewed in order to avoid losing information. For example, olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (NICE TA620) has two separate recommendations for different indications. While a patient who has a BRCA1 or BRCA2 mutation and has had three or more courses of platinum-based chemotherapy is eligible for the treatment, a patient who has a BRCA1 or BRCA2 mutation and has had two courses of platinum-based chemotherapy is able to use the treatment within Cancer Drug Fund. Consequently, these indications are included separately in the analysis.

Step 2: data extraction

A detailed protocol is developed to guide the extraction of essential data for each appraisal in order to investigate the use of RWD in NICE TAs in a systematic and reproducible manner. The protocol is designed to extract information from both the manufacturer’s submission (manufacturer’s cost-effectiveness analysis) and the final appraisal document (the model preferred by the committee) regarding where RWD were used, and to determine the extent to which the committee supported the use of RWD in these appraisals and understand what factors are associated with supporting or not supporting their use. Figure 2 shows the structure of the data extraction template. In summary, the extraction tool consists of three parts—general information, explanatory variables and outcome variables. The outcome of interest being the use of RWD. The outcome variables record use or non-use of RWD for different elements of the economic evaluation. The information in the base-case analysis and sensitivity analyses will be separately extracted. The tool includes all important elements of an economic
evaluation. The study will analyse the data to investigate patterns in the use of RWD in NICE appraisals, and the association between several factors and the use of RWD. Explanatory variables are suggested based on the hypotheses presented under step 4: data analysis. All items in the extraction template and how to code them are described in the glossary (online supplemental file 1). To convey the type of information to be extracted, some examples from a preparatory review are presented in the glossary.

Parametric and non-parametric use

This protocol distinguishes two categories of outcome variable, parametric and non-parametric use of RWD. Parametric use of RWD is the use of such data to define the numerical value of a specific variable in the economic evaluation, whereas non-parametric use is where data are used to develop the model structure or to determine the scope of the evaluation. For example, when RWD are used to estimate survival, this will be counted as parametric use with respect to clinical outcomes (overall survival/progression free survival). Parametric use is reviewed and recorded for the intervention and comparators separately as different data could be used in the cost-effectiveness analysis. An example of non-parametric use of RWD can be found in the appraisal of palbociclib for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (NICE TA495). In this appraisal, the company used information from a study of medical records to determine the subsequent treatments to be assumed in the economic model. This case is regarded as non-parametric use since RWD were used to specify the treatment sequence but not the quantity and cost of subsequent treatment.

Parametric and non-parametric use of RWD and the different categories shown in figure 2 facilitate more consistent data extraction by highlighting the different ways RWD might be used, and provide greater flexibility when testing hypotheses regarding the use of RWD, and the exploration of ways to measure the intensity of use of RWD.

Coding

A key issue with respect to improving the reliability of data extraction is how many distinct variables to identify and how finely to divide the potential responses to these variables. One option, in order not to lose information, is to have many distinct variables with binary responses. Another option is to merge many variables but have multilevel responses. This coding system has advantages which include avoiding information loss, and also grouping together ‘similar’ information used during appraisals to establish patterns of the use of RWD. This is closely linked to the reason for not using multiple responses in the coding. The template takes an ‘including all and combining trivia’ approach. It helps to include all relevant variables where RWD data can potentially be used, but also to list variables more concisely by merging unnecessarily trivial variables so that the outcome of the extraction can be concretely analysed. Based on two categories, the parametric and non-parametric use of RWD, the areas where data are likely to be used are carefully searched. As a backbone of the extraction structure, distinguishing two categories helped to search each component systematically. Under parametric use, clinical effectiveness, health utility and cost and healthcare resource use were thoroughly reviewed. After sorting variables, they were aggregated if the information is minor and can be categorised into one variable. The area where aggregation is mostly required is resource use. In order to reflect routine clinical practice, especially the cost part has naturally incorporated RWD into the analysis. Estimates of unit costs are
usually informed by the National Health Service (NHS) reference costs (a form of RWD) and thus in order to provide a more sensitive measure of the use of RWD the extraction template focuses on resource use (with respect to cost). However, the measures of resource use are not fully differentiated. Different health technologies include different elements of resource use reflecting their characteristics. Distinguishing all resource use is not an accurate way to understand why and how RWD were used. Although all individual resource uses are not identified, some resource uses, which can be critical in appraisals are differentiated. Variables such as volume of treatment or dose adjustment have potentially critical impacts on the result of economic evaluation. Therefore, these variables are separated from overall resource use.

**Step 3: validation of data extraction tool**

The data extraction tool will be validated by a second researcher independently repeating the data extraction for a random sample of appraisals (20% of all appraisals). This validation is required to check the replicability of the data extraction and the clarity of the extraction tool. Any disagreements between the researchers will be resolved by discussion. Peer discussion following the validation process is important not only to check the clarity of this protocol but also to investigate any deviations caused by unclear information. It will help pinpoint where a higher degree of subjectivity may arise in the data extraction.

**Step 4: data analysis**

The extracted data will be analysed quantitatively in two different ways. First, counts and proportions will summarise where and how RWD have been used in appraisals. This will be supplemented by an analysis of the intensity of use of RWD in order to explore changes in the pattern of use of RWD over time and differences with respect to cancer type. In addition to descriptive statistics, the association between years and the intensity of use of RWD will be examined. Second, a regression analysis will be performed to investigate which factors are associated with the greater use of RWD in a company’s submission. As part of the protocol development, some appraisal documents were reviewed to identify factors potentially associated with the use of RWD. Five factors were identified and formulated into hypotheses about increased use of RWD (figure 3).

1. Poor internal/external validity of the clinical trial is associated with greater use of RWD.
2. Absence of direct (head-to-head) comparison is associated with greater use of RWD.
3. Low incidence rate of the disease is associated with greater use of RWD.
4. Immature survival data in the clinical trial are associated with greater use of RWD.
5. The technology having been recommended in previous NICE TA guidance is associated with greater use of RWD.

**Figure 3** Hypotheses about increased use of real-world data (RWD). NICE, National Institute for Health and Care Excellence; TA, technology appraisal.

**Methodological issues**

The design of this data extraction protocol, in which information is reliably and repeatedly extracted across appraisals, will allow us to review evidence for the use of RWD more systematically than could be obtained from conducting several case studies. However, several methodological challenges can be anticipated. This section addresses these challenges and how they might be mitigated.

**Issue 1: unclearly stated information**

Overall, NICE appraisals clearly describe the data used in the evidence synthesis. However, sometimes the search process may not be well-documented and the precise source of information may not be clear. Systematic literature reviews are carried out to identify all relevant evidence in appraisals. Clinical effectiveness evidence is carefully examined and described in detail, with clear reasons for the inclusion and exclusion of studies. On the other hand, the systematic search for resource use and cost information usually enumerates miscellaneous studies with bibliographic information and a summary, but the critical review of minor components of health cost is sometimes missing. While manufacturers provide the result of their assessments, some manufacturers’ submissions do not clearly state whether a particular study was used to determine an element of resource use making up the health state costs. However, it appears to be rare for there not be an explicit statement regarding the evidence used, mostly with respect to resource use.

**Issue 2: level of aggregation**

An important question is the most appropriate level of aggregation. This is best illustrated with respect to healthcare costs. It would be possible to have a variable indicating use or non-use of RWD for every single element of cost (distinguishing general practice (GP) visits, frequency of hospitalisation, etc). At the opposite extreme, there could be a single cost variable which indicated whether RWD were used for any element of cost. The more aggregated the measure the greater the loss of information, but some elements of cost are much more important than others and the potential analyses of the use of RWD will multiply greatly if there is no attempt at aggregation. The current protocol tries to balance the advantages and disadvantages of different levels of aggregation by combining several elements into a health state cost variable but distinguishing other important components of cost, such as volume of treatment, dose adjustment and resource use for adverse events.

**Issue 3: no consensus on the definition of RWD**

This research uses a definition of RWD merging definitions from the FDA and Makady et al. The distinctive part of the definition used in this research is ‘routinely collected’ data from a ‘non-experimental study’. Although this definition provides a specific and clear definition for this research, there is no consensus on the best...
definition of RWD. Even the same definition can be interpreted in different ways. For example, some researchers interpret that routinely collected in the FDA definition is ‘collected in routine care’ whereas other interpret it as ‘how frequently data are collected.’ It is likely that other definitions of RWD are preferred by other researchers and the data extracted will be influenced by the definition of RWD chosen. While the use of multiple definitions of RWD was considered, it would create practical problems such as multiplying the number of potential analyses and making data extraction take longer. Although the chosen definition can be questioned by other researchers who have different views, the various definitions overlap considerably. It is thus unlikely there will be a marked divergence in the data extracted when using the different definitions.

Design to mitigate methodological issues
Several operational rules have been designed to minimise bias likely to come from the methodological issues encountered in the data extraction. First, ‘not clear’ is recorded separately in order to provide a more accurate description of the use of RWD. However, for purposes of data analysis, we anticipate treating these instances as ‘no RWD’ since the code not clear cannot be independently analysed. In addition, having a not clear category in analysis is unlikely to improve data quality since we anticipate that this problem will arise in very few appraisals. Also, information which is not clearly recorded in the appraisal documents is usually not important information with respect to the evidence synthesis. The approach (extracting all relevant information which can provide meaningful data for analyses) is also closely linked to the reason for using binary code for analysis in this research. Decomposing levels of codes into several small parts can facilitate data extraction. However, it is more likely to increase the complexity since trivial information is individually recorded. The extracted trivial data should be interpreted based on another operational rule. It is subject to increased error, particularly when testing hypotheses. For these reasons, the benefit of using multilevel codes does not outweigh the benefit of binary codes while separation is much more time consuming. Instead of adapting multilevel codes, this study will adopt an alternative approach, an intensity analysis which helps to identify important differences within the diverse patterns of use of RWD. When looking at the pattern of use of RWD, the intensity of use will be analysed. Simply counting the number of times RWD are used is not an accurate way to understand why and how RWD were used. Alternatively, this study focuses on variables which are potentially important determinants of cost-effectiveness in appraisal. Variables such as survival outcome, volume of treatment and choice of comparators are more likely to influence estimated cost-effectiveness. Especially, the survival outcome is the most important information in both clinical and cost-effectiveness as well as one of the controversial areas where to use RWD. The intensity analysis is a framework to show whether RWD are used in these components alongside the quantity of the use of RWD. It can offer more benefits in deeper understanding of the use of RWD than counting all miscellaneous uses of RWD.

Strengths and limitations
To the best of the authors’ knowledge, this is the first study protocol to investigate to what extent RWD have been used in NICE appraisals. It allows the practice of extracting information to be reproducible, systematic and transparent. Strengthening the reproducibility and transparency of data extraction can maximise understanding of the use of RWD by allowing more accurate interpretation and use of findings. This protocol could be relevant to researchers or HTA agencies who aim to understand how various data resources are used in HTA in England. Analysis of data generated using this protocol can provide a detailed picture of the use of RWD in NICE appraisals over 10 years. Moreover, the study findings could add value to NICE’s ongoing work to broaden the evidence used in appraisals.

The protocol has the limitation that it has been developed to study the use of RWD in NICE appraisals of oncology drugs. Consequently, the data extraction protocol may not be fully applicable to appraisals in other disease areas or to the different practice of other HTA bodies. Since the documentation is significantly different depending on each country’s context, it may not be feasible to extract the same information as in the English context. However, many of the distinctions are of wider application, for example, parametric versus non-parametric use of RWD, and the taxonomy of where in an economic evaluation it might be relevant to look for use of RWD. Also, the hypotheses are potentially of wider application. The results are going to be specific to NICE but otherwise the structure of this research has wider application. Although not fully transferrable, this protocol can be modified for use in other HTA contexts. Lastly, this protocol focuses on four main documents. Relevant RWD may arise at the clarification or technical engagement stage. It is possible there is some information regarding use of RWD that is not reported in any of the four main documents. However, only a small number of such cases are anticipated. If RWD are critically used in a revised model and the committee thinks it is an important change, this evidence is likely to be addressed in the FAD.

ETHICS AND DISSEMINATION
This study was approved by the Ethics Committee of the London School of Hygiene and Tropical Medicine on 14 November 2019 (17315). Results will be published in peer-reviewed journals.

Acknowledgements The authors thank Dr Alec Miners and Dr David Lugo-Palacios for useful advice on the clarity of data extraction and the validation process.

Contributors Both authors contributed to conceptualising and designing the study. JK drafted the protocol manuscript. JC revised the manuscript for important intellectual content and contributed to the methodology.
REFERENCES


Figure 1 Inclusion/exclusion criteria

<table>
<thead>
<tr>
<th>Inclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>- STA of oncology medicine</td>
</tr>
<tr>
<td>- Appraisals issued from January 2011 to May 2021</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Exclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Appraisal of technology for preventing the complications of cancer</td>
</tr>
<tr>
<td>- Appraisal of surgical practice and other therapeutic therapies</td>
</tr>
<tr>
<td>- Appraisals for which evidence is not available (withdrawn appraisals) or was never supplied (terminated appraisals)</td>
</tr>
</tbody>
</table>
Figure 2 The framework for data extraction

**Required data**

**General information**
- Type of cancer
- Technology of interest
- TA reference number
- Replace
- Targeted cancer therapy
- Recommendation
- Number & name of comparators
- Name of manufacturer & ERG
- Published date of final scope & MS* & FAD

**Explanatory variables**
- Incidence rate
- Head-to-head comparison
- RCTs (name, intervention, comparators)
- Number of events (overall survival) in main clinical study
- Recommendation status

**Outcome variables**

**Parametric use**

**Non-parametric use**

**Clinical outcome**
- Overall survival (OS)
- Progression-free survival (PFS)
- Time to disease progression (TTP)
- Adverse event (AE)

**Transition probability**

**Health utility**
- Generic measurement
- Condition specific measurement
- Disability of adverse event

**Resource use**
- Health state cost
- End-of-life care
- Managing AE
- Volume of treatments
- Dose adjustment

**Characteristics of population**

**Treatment sequence**

**Choice of comparators**

**Structure**
- Health state
- Model cycle
- Survival distribution
- Time to discontinuation

* Published date of MS: the date when it was submitted by the manufacturer, which is stated on manufacturer submission document
Figure 3 Hypotheses about increased use of RWD

1) Poor internal/external validity of the clinical trial is associated with greater use of RWD.
2) Absence of direct (head-to-head) comparison is associated with greater use of RWD.
3) Low incidence rate of the disease is associated with greater use of RWD.
4) Immature survival data in the clinical trial are associated with greater use of RWD.
5) The technology having been recommended in previous NICE TA guidance is associated with greater use of RWD.
### Supplement 1 Glossary of variables in extraction template

<table>
<thead>
<tr>
<th>General information</th>
<th>Explanation</th>
<th>Coding</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Variable</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Type of cancer</td>
<td>The NICE classification of the cancer (website: <a href="https://www.nice.org.uk/guidance/conditions-and-diseases/cancer">https://www.nice.org.uk/guidance/conditions-and-diseases/cancer</a>)</td>
<td>Bladder cancer=1, Blood and bone marrow cancer =2, Breast cancer=3, Colorectal=4, Neuroblastoma=5, Head and neck=6, Liver=7, Lung=8, Oesophageal=9, Ovarian=10, Pancreatic=11, Prostate=12, Renal=13, Skin=14, Stomach=15, Sarcoma=16</td>
</tr>
<tr>
<td>Technology of interest</td>
<td>The name of drug in the current appraisal. If it is combination therapy, the key technology which manufacturer focuses on will be taken here.</td>
<td>Narrative description</td>
</tr>
<tr>
<td>Indication</td>
<td>Clinical indications which are addressed in Final Appraisal Determination (FAD) document</td>
<td>Narrative description</td>
</tr>
<tr>
<td>TA number</td>
<td>the reference number of the technology guidance</td>
<td>Narrative description</td>
</tr>
<tr>
<td>Replace</td>
<td>Whether TA guidance has replaced or not. Appraisals can be replaced after rapid reviews/reviews/updates of previous appraisals or CDF reviews. Regardless of reasons of replacement, TA reference number which is replaced by this appraisal of interest will be recorded.</td>
<td>None= 0 If current appraisal replaces previous appraisal, the replaced TA reference number is recorded here.</td>
</tr>
<tr>
<td>Pre-2016 CDF reconsideration</td>
<td>Before April 2016, the drug which was not reviewed or not recommended for routine commissioning by NICE can be used using the previous model of CDF. When new CDF was introduced in April 2016, these drugs in the old CDF were appraised by NICE to transit the model of CDF. This variable describe whether the appraisal of interest is an appraisal of the CDF reconsideration for the drug used in the old model of CDF before 2016.</td>
<td>No, it is not pre-2016 CDF reconsideration =0 Yes, it is a appraisal of pre-2016 CDF reconsideration =1</td>
</tr>
<tr>
<td>2016 CDF review</td>
<td>In April 2016, a new model of CDF was introduced. In the new model, an additional recommendation, recommended for use within the CDF can be used when NICE appraising cancer drugs. The drug available via the CDF has to collect the data for further review for the routine commissioning after a certain period. As this mandated data collection can impact on the use of RWD, this variable allows to distinguish the appraisals, which RWD is more likely to be used.</td>
<td>No, it is not 2016 CDF review =0 Yes, it is 2016 CF review=1</td>
</tr>
<tr>
<td>Targeted cancer therapy</td>
<td>Treatment that uses drugs or other substances to identify and attack specific types of cancer cells</td>
<td>Non-targeted therapy = 0, targeted therapy = 1, not sure = Narrative description</td>
</tr>
</tbody>
</table>
### Recommendation

The classification of recommendations made by the NICE committee in FAD document:
- Not recommended: 0
- Recommended (in line with marketing authorisation): 1
- Recommended (in line with marketing authorisation) in CDF: 2
- Optimised: 3
- Optimised in CDF: 4
- Recommended in research: 5

### Number of Comparators

Count the number of comparators in each manufacturer submission or FAD document. The information in manufacturer submission and FAD is recorded in the separated rows (manufacturer row/committee row).

### Name of Comparators

Record the name of comparators in manufacturer submission or FAD document.

### Name of Manufacturer

The name of manufacturer in manufacturer submission.

### Name of the ERG

The name of the ERG (evidence review group)/AG (assessment group) in ERG critiques or AG reports.

### Published Date of Final Scope

The date of final scope as MM/YYYY.

### Published Date of Manufacturer

The date of manufacturer submission as MM/YYYY.

### Published Date of FAD Guidance

The date of FAD document as MM/YYYY.

### Explanatory Variables

<table>
<thead>
<tr>
<th>Variable</th>
<th>Explanation</th>
<th>Coding</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incidence (rate, year)</td>
<td>The rate would be recorded as it is in the appraisal. Incidence rate could be found in the final scope document or in manufacturer submission document. If the figures are not identical in each document, the latest rate is recorded. Most appraisals present the annual estimate of the number of patients who are eligible for the treatment in the “Budget Impact” section of company submission. This number is mainly used for the incidence. If this information is not available in the appraisal, the number in previous appraisal for similar indication is used instead.</td>
<td>Number</td>
</tr>
<tr>
<td>H2H</td>
<td>Whether the head-to-head clinical trial of a technology of interest exists or not, which compares with agreed comparators. The information is most likely to be found in the section: Identification and selection of relevant studies in clinical effectiveness part.</td>
<td>no=0, yes=1, yes but some comparators missing =2</td>
</tr>
<tr>
<td><strong>ITC</strong></td>
<td>ITC (indirect treatment comparison). The information could be found in the section: Indirect and mixed treatment comparisons in clinical effectiveness part.</td>
<td>no=0, yes=1</td>
</tr>
<tr>
<td><strong>RCT (technology of interest)</strong></td>
<td>Main RCT used in the appraisal: the name of the H2H RCT, if it exists. Unless there is an H2H, RCT refers to the clinical trial of technology of interest in the ITC.</td>
<td>no=0, yes=1</td>
</tr>
<tr>
<td>- <strong>Name of RCT</strong></td>
<td>The name of the aforementioned RCT</td>
<td>Narrative description</td>
</tr>
<tr>
<td>- <strong>Intervention in RCT</strong></td>
<td>The name of the intervention used in the aforementioned RCT. This variable helps to identify the main technology in RCT when technology is appraised as combination therapy.</td>
<td>Narrative description</td>
</tr>
<tr>
<td>- <strong>Comparators in RCT</strong></td>
<td>The comparator of the aforementioned RCT</td>
<td>Narrative description</td>
</tr>
<tr>
<td>- <strong>Size of RCT</strong></td>
<td>The number of participants in the aforementioned RCT</td>
<td>Number</td>
</tr>
<tr>
<td>- <strong>Median duration of follow-up</strong></td>
<td>The median duration of follow-up in the aforementioned RCT. If it is not reported, record as NR (not reported). Unit: month Not reported = ..</td>
<td></td>
</tr>
<tr>
<td><strong>Anchored/unanchored</strong></td>
<td>“Anchored” means that RCT of technology of interest exists, and the RCT has been linked to any other studies which evaluate the drug’s effectiveness. “Unanchored” means that the clinical outcome study doesn’t have any comparators which connect to other studies. For example, comparing a single-arm study with a single-arm study is “unanchored”. Also, RCTs compared without common comparators in ITC is “unanchored”. Not anchored=0, Anchored =1</td>
<td></td>
</tr>
<tr>
<td><strong>MAIC/STC</strong></td>
<td>Matching adjusted indirect comparison (MAIC), Simulated Treatment Comparison (STC). A methodology of making adjustment to increase the comparability of two distinct populations mostly among unanchored studies. But it could be used in anchored studies in case where the two populations in ITC is starkly different from each other. Naive=0, MAIC=1 STC=2 Other methods=3</td>
<td></td>
</tr>
<tr>
<td><strong>Risk of bias (RoB) of RCT (direct quotation)</strong></td>
<td>In order to evaluate the internal validity of RCTs, the risk of bias, which was reported in the ERG report, will be recorded here. Information is available at the quality assessment part of the ERG report. The ERG assesses the risk of bias of the included study using quality assessment tools. The ERG statement is directly quoted. The ERG often addresses the issue of quality of study narratively. Moreover, the ERG uses different terminology, whereas the domain of assessment is consistent. Therefore, the risk of bias would be narratively recorded. Prior to analysis, it will be scored by looking at the number of factors about which the ERG has expressed concern. Direct quotation from ERG documents</td>
<td></td>
</tr>
<tr>
<td><strong>Risk of bias in RCT (grade)</strong></td>
<td>In order to conduct statistical analysis, a set of codes will be used here. The direct quotation will be classified into four groups following the number of risk factors. High/good quality without mentioned weakness= 0, risk factor 1 (low) =1, risk factor 2-3 (moderate)=2, risk factor 4</td>
<td></td>
</tr>
</tbody>
</table>
As narrative accounts, generalisability of RCT is reported in the ERG report whether the population of RCT properly represents the UK general population in terms of aging structure, health status and health care practice (practice-dose, subsequent treatment, etc.).

### Direct quotation from ERG documents

**Representative without mentioned weakness** = 0, **Representative but minor concerns** = 1, **Questionable generalisability** = 2

- **Previously recommended in other indication**
  - Whether the technology has been recommended for other types of cancers besides the current indication of the technology.
  - No = 0, Yes including all recommend, CDF, Optimised, Optimised (cdf) = 1

- **TA number & date of appraisal in other indication**
  - If it was recommended for other indications, record the TA number and the date of the FAD documents (MM/YYYY).
  - Narrative description of date

- **Previous recommended treatment in the same cancer**
  - Whether the technology has been recommended for other treatment lines in the same type of cancer.
  - No = 0, Yes including all recommend, CDF, Optimised, Optimised (cdf) = 1

- **TA number & date of appraisal in the same cancer**
  - If it was recommended for other treatment lines in the same cancer category, record the TA number and the date of the FAD documents (MM/YYYY).
  - Narrative description of date

### Maturity of survival data in clinical trial

The data maturity is examined by looking at the number of events (deaths) of intervention arm in clinical trials. In published appraisal document, some of the information is redacted due to confidentiality. If the information is not available, the article of clinical trial published in journals is searched in order to check how many events are observed during the trial. Nonetheless, data are still not available in some cases. Since manufacturer is likely to redact the OS information when median OS was not reached. Hence, the survival data in this case are regarded as immature.

### Maturity (grade)

The direct quotation will be classified into three groups following the data cut point, 20% and 50% of the number of events. This protocol adapts the criterion for measuring maturity of survival data in Tai et al. which investigates data maturity in STAs by looking at the proportion of death in pivotal trials. In the study, 20, 50 and 70 % of proportion of number of deaths are used to discuss the maturity of survival data (1). This protocol only uses 20% and 50% to assess the maturity without the category "unclear."

<table>
<thead>
<tr>
<th>Variable</th>
<th>Explanation</th>
<th>Coding</th>
<th>Example</th>
</tr>
</thead>
<tbody>
<tr>
<td>Outcome variables</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Variable</td>
<td>Explanation</td>
<td>Coding</td>
<td>Example</td>
</tr>
<tr>
<td>BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### characteristic of population

<table>
<thead>
<tr>
<th>Usage of RWD</th>
<th>Example</th>
</tr>
</thead>
<tbody>
<tr>
<td>Soft use</td>
<td>When RWD are supplementary evidence to decide the population characteristics</td>
</tr>
<tr>
<td>Hard use</td>
<td>When RWD determine the characteristics of population in economic evaluation</td>
</tr>
</tbody>
</table>

#### No RWD = 0  
#### Yes, data from RWD = 1  
#### Not clear = 9

- **Pomalidomide**, in combination with low-dose dexamethasone, for treating multiple myeloma in adults at third or subsequent relapse (NICE TA427): baseline patient characteristics were obtained from RWD collected from a hospital population since the majority of the trial populations were previously untreated, which was different from target population.

---

### treatment sequence

<table>
<thead>
<tr>
<th>Usage of RWD</th>
<th>Example</th>
</tr>
</thead>
<tbody>
<tr>
<td>No RWD</td>
<td>When RWD are used to determine the subsequent treatment option or not. After the disease progression onto the later stages of cancer treatments, patients are likely to receive idiosyncratic subsequent treatments. The pattern of subsequent treatment for cost-effectiveness analysis could be observed by RCT or RWD.</td>
</tr>
</tbody>
</table>

#### No RWD = 0  
#### Yes, data from RWD = 1  
#### Not clear = 9

- **Palbociclib** with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (NICE TA495): a study of medical records was used to determine the treatment sequence.

---

### choice of comparator

<table>
<thead>
<tr>
<th>Usage of RWD</th>
<th>Example</th>
</tr>
</thead>
<tbody>
<tr>
<td>No RWD</td>
<td>When RWD are used to choose the comparators in economic evaluation or not. Although comparators are chosen based on the current clinical guideline, drug utilisation data or clinical expert opinion are frequently referred to find the most relevant comparators in evaluation.</td>
</tr>
</tbody>
</table>

#### No RWD = 0  
#### Yes, data from RWD = 1  
#### Not clear = 9

- **Ixazomib** with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (NICE TA505): the manufacturer considered that lenalidomide was appropriate comparator based on IMS market research data (lenalidomide, 69% market share and panobinostat, 7%).

---

### structure (health state)

<table>
<thead>
<tr>
<th>Usage of RWD</th>
<th>Example</th>
</tr>
</thead>
<tbody>
<tr>
<td>No RWD</td>
<td>When RWD are used to determine the health state such as stable, progression, and death in a given model. Information is available at health state in the model of cost-effectiveness analysis in manufacturer submission documents.</td>
</tr>
</tbody>
</table>

#### No RWD = 0  
#### Yes, data from RWD = 1  
#### Not clear = 9

- **Palbociclib** with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (NICE TA495): the model health state of post-progression was specified based on a retrospective patient medical record review study.

---

### structure (model cycle)

<table>
<thead>
<tr>
<th>Usage of RWD</th>
<th>Example</th>
</tr>
</thead>
<tbody>
<tr>
<td>No RWD</td>
<td>When RWD are used to determine model cycle or not. Model cycle, hereby, means that the duration between different health states, which can be influenced by the severity of conditions.</td>
</tr>
</tbody>
</table>

#### No RWD = 0  
#### Yes, data from RWD = 1  
#### Not clear = 9

N/A **

---

### Structure (survival distribution of intervention)

<table>
<thead>
<tr>
<th>Usage of RWD</th>
<th>Example</th>
</tr>
</thead>
<tbody>
<tr>
<td>No RWD</td>
<td>When RWD are used to decide the survival distribution of intervention or not. Since survival rate observed in RCTs is immature, it is necessary to extrapolate the survival rate for analysis. In order to choose proper survival distribution, the goodness of fit is tested (AIC, BIC).</td>
</tr>
</tbody>
</table>

#### No RWD = 0  
#### Yes, data from RWD = 1  
#### Not clear = 9

- **Larotrectinib** for treating advanced solid tumours with NTRK fusions (NICE TA630): UK all-cause mortality data were used to assess the clinical acceptability of distributions whether patient overall survival exceeded current UK life expectancy.
Also, the clinical plausibility is asked to validate the distribution. In this case, the alternative data can be utilized.
- If RWD is utilised for choosing distribution, mark as “hard use”.
- If RWD is utilised as supplementary evidence for the chosen distribution, mark as “soft use”.

<table>
<thead>
<tr>
<th>Structure (survival distribution of comparator)</th>
<th>Whether RWD are used to validate the feasibility of survival distribution of comparator or not.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>As survival distributions of intervention and comparators are separately determined, the extraction tool approach it independently. Apply the abovementioned description on survival distribution of intervention to comparator in this row.</td>
</tr>
<tr>
<td>No RWD = 0</td>
<td>Yes, data from RWD = 1</td>
</tr>
<tr>
<td>Not clear = 9</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Structure (Time to discontinuation of intervention)</th>
<th>Whether RWD are used to decide the time to discontinuation of intervention or not.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>The time to discontinuation is likely to be decided by 1) simply adopting discontinuation rule in trials, 2) formulating distribution of discontinuation, or 3) clinical experts' opinion.</td>
</tr>
<tr>
<td></td>
<td>- If RWD are used for designating the time to discontinuation, mark as “hard use”</td>
</tr>
<tr>
<td></td>
<td>- If RWD are used as supplementary evidence for designating the time to discontinuation, mark as “soft use”.</td>
</tr>
<tr>
<td></td>
<td>- If clinical experts' opinions are used for designing the time to discontinuation, it is not regarded as RWD.</td>
</tr>
<tr>
<td>No RWD = 0</td>
<td>Yes, data from RWD = 1</td>
</tr>
<tr>
<td>Not clear = 9</td>
<td></td>
</tr>
</tbody>
</table>

- Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer (NICE TA628): The plausibility of the extrapolation of time on treatment was validated by UK RWD, hospital network data.

<table>
<thead>
<tr>
<th>Structure (time to discontinuation of comparator)</th>
<th>Whether RWD are used to decide the time to discontinuation of comparator or not.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Apply the above-mentioned description on time to discontinuation of intervention to comparator in this</td>
</tr>
<tr>
<td>No RWD = 0</td>
<td>Yes, data from RWD = 1</td>
</tr>
<tr>
<td>Not clear = 9</td>
<td></td>
</tr>
</tbody>
</table>
| Clinical outcome/Comparators | Whether RWD give the figure for overall survival (OS) of intervention or not. In order to measure the Quality Adjusted Life-Years (QALYs), it is necessary to extrapolate overall survival based on observed data on survival. The survival data could come from RCT or RWD. | No RWD = 0  
Yes, data from RWD = 1  
Not clear = 9 | - Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease (NICE TA558): the survival model applied the registry data (American Joint Committee on Cancer; AJCC) to both treatment arms after a certain time point. |
|-----------------------------|--------------------------------------------------------------------------------------------------|-------------------------------|------------------------------------------------------------------------------|
| Clinical outcome (PFS)      | Whether RWD give the figure for progression free survival (PFS) of intervention or not. The progression of disease is important for economic evaluation model in terms of health state transitions and treatment switching. The survival data could come from RCT or RWD. | No RWD = 0  
Yes, data from RWD = 1  
Not clear = 9 | N/A**                                                                 |
| Clinical outcome (RR)       | Whether RWD provides the response rate (RR) for the intervention or not. Theeffectiveness of cancer treatment is often shown by responses of tumour cells, which is evaluated by the RECIST criteria or other criteria. The response rate data would be collected in RCT or other type of data. | No RWD = 0  
Yes, data from RWD = 1  
Not clear = 9 | N/A**                                                                 |
| Clinical outcome (TTP)      | Whether RWD give the figure for time-to-progression (TTP) of intervention or not. Some cancer treatments show their clinical effectiveness not through the progression free survival (PFS), but alternatively through time-to-progression. | No RWD = 0  
Yes, data from RWD = 1  
Not clear = 9 | N/A**                                                                 |
| Clinical outcome (AE)       | Whether RWD give the figure of adverse event (AE) of intervention or not. Adverse events are crucial information for the estimation of the QALYs. The adverse events are collected in RCT. However, RWD, including cohort studies, retrospective studies, or other type of studies, also provide the information of adverse events, which cannot be found in RCT. | No RWD = 0  
Yes, data from RWD = 1  
Not clear = 9 | - Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity (NICE TA589): retrospective non-interventional cohort study collected from 2000 to 2017 was used to inform the clinical outcome of comparators as well as adverse event. |
| Clinical outcome (OS)       | Whether RWD give the figure of overall survival (OS) of comparators or not. | No RWD = 0  
Yes, data from RWD = 1  
Not clear = 9 | Refer to the variable, clinical outcome (OS) intervention |
<table>
<thead>
<tr>
<th>Clinical outcome</th>
<th>Whether RWD provide the figure for the progression free survival (PFS) of comparators or not.</th>
<th>No RWD = 0</th>
<th>Yes, data from RWD = 1</th>
<th>Not clear = 9</th>
<th>N/A**</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical outcome (RR) comparators</td>
<td>Whether RWD provide the response rate (RR) of comparators or not.</td>
<td>No RWD = 0</td>
<td>Yes, data from RWD = 1</td>
<td>Not clear = 9</td>
<td>N/A**</td>
</tr>
<tr>
<td>Clinical outcome (TTP) comparators</td>
<td>Whether RWD provide the time-to-progression (TTP) of comparators or not.</td>
<td>No RWD = 0</td>
<td>Yes, data from RWD = 1</td>
<td>Not clear = 9</td>
<td>N/A**</td>
</tr>
<tr>
<td>Clinical outcome (AE) comparators</td>
<td>Whether RWD provide the figure adverse events (AE) for the comparators or not.</td>
<td>No RWD = 0</td>
<td>Yes, data from RWD = 1</td>
<td>Not clear = 9</td>
<td>Refer to the variable, clinical outcome (AE) intervention</td>
</tr>
<tr>
<td>Transition probability</td>
<td>Whether RWD provide the transition probability from one state to other state, if it is applicable.</td>
<td>No RWD = 0</td>
<td>Yes, data from RWD = 1</td>
<td>Not clear = 9</td>
<td></td>
</tr>
<tr>
<td>Health utility of health state (generic)</td>
<td>Whether health state utility survey of generic measurement is done in RWD or RCT. Health state utility is necessary information for the estimation of the QALYs. Generic health utility measurement, EQ-5D, is frequently used. There is national tariff of EQ-5D to get the scores. Hereby, the way of collecting survey (RWD or RCT) is highlighted.</td>
<td>No RWD = 0</td>
<td>Yes, data from RWD = 1</td>
<td>Not clear = 9</td>
<td>N/A**</td>
</tr>
<tr>
<td>Health utility of health state (condition-specific)</td>
<td>Whether health state utility survey of condition-specific measurement is done in RWD or RCT. In cancer treatment, condition-specific measurement is commonly adopted. Similar to the previous row, the way of collecting survey (RWD or RCT) is highlighted.</td>
<td>No RWD = 0</td>
<td>Yes, data from RWD = 1</td>
<td>Not clear = 9</td>
<td>N/A**</td>
</tr>
</tbody>
</table>
| Disutility of adverse events | Whether survey of collecting disutility data is done in RWD or RCT. As adverse events are likely to reduce the patient’s quality of life, the disutility of adverse events is included in estimates. The way of collecting survey (RWD or RCT) is drawn to attention. | No RWD = 0  
Yes, data from RWD = 1  
Not clear = 9 | N/A** |
| --- | --- | --- | --- |
| Resource use (Health state cost) common | Whether resource use for estimating health state cost is derived from RWD or RCT. In economic evaluation, the unit cost mostly comes from the national reference cost. The total cost is calculated by the total resource use (volume of technology and health care services) multiplied by the reference cost. Here, the only resource use is focused in data extraction. Resource use for estimating health state cost includes all activity like monitoring, GP visits, pharmacy cost etc. Health state resource use could be aggregated or individually listed. Here, the difference of describing health state cost is not separately considered. | No RWD = 0  
Yes, data from RWD = 1  
Not clear = 9 | - Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies (NICE TA559): RWD was used for estimating the cost of inpatient admission (data: Hospital Episode Statistics), the cost of home care and hospice (data: National Audit Office), and GP time (data: Personal Social Services Research Unit; PSSRU). |
| Resource use (end-of-life care) common | Whether resource use for estimating end-of-life care is derived from RWD or RCT. Resource use of terminal cancer patients is not frequently reported in the RCT providing the treatment effect. Therefore, other data resources, including RCTs of other technologies, provide the information of resource use in the end-of-life care. | No RWD = 0  
Yes, data from RWD = 1  
Not clear = 9 | N/A** |
| Resource use (Managing AE intervention) | Whether resource use for managing adverse events of intervention is derived from RWD or RCT. Resource use of managing adverse events is reported in RCTs as well as in other types of researches which can provide alternative perspectives. | No RWD = 0  
Yes, data from RWD = 1  
Not clear = 9 | N/A** |
| Resource use (volume of treatment) intervention | Whether resource use for volume of treatment of intervention is derived from RWD or RCT. In this study, scope of the volume of treatment is limited to the frequency of treatment, frequency of administration, and amount of subsequent treatment. | No RWD = 0  
Yes, data from RWD = 1  
Not clear = 9 | - Fulvestrant for treating untreated locally advanced or metastatic oestrogen-receptor positive breast cancer (NICE TA503): a medical chart review study was used to determine the proportion of patient using subsequent treatment for cost calculation. |
| Resource use (Dose adjustment) intervention | Whether resource use for dose adjustment of intervention is derived from RWD or RCT. There are several reasons for adjusting dose such as adverse events (AEs). The dose of cancer treatments is calculated by BSA (body surface area). This study focuses only on BSA and dose adjustment due to AEs, because these information are commonly reported in NICE appraisals. | No RWD = 0  
Yes, data from RWD = 1  
Not clear = 9 | N/A** |
|------------------------------------------|-------------------------------------------------------------------------------------------------|----------------------------------------|--------|
| Resource use (Managing AE) comparators   | Whether resource use for managing adverse events of comparators is derived from RWD or RCT.   | No RWD = 0  
Yes, data from RWD = 1  
Not clear = 9 | N/A** |
| Resource use (volume of treatment) comparators | Whether resource use for volume of treatment of comparators is derived from RWD or RCT. | No RWD = 0  
Yes, data from RWD = 1  
Not clear = 9 | Refer to the variable, resource use (volume of treatment) intervention |
| Resource use (Dose adjustment) comparators | Whether resource use for dose adjustment of comparators is derived from RWD or RCT. Since the intervention is a novel technology, RCTs provide less information on the adjustment. RWD could be utilised to provide more relevant information regarding dose adjustment of existing technologies which have been used in routine clinical practice. | No RWD = 0  
Yes, data from RWD = 1  
Not clear = 9 | N/A** |

* In order to detect the use of RWD in sensitivity analysis, the parametric part is duplicated.
** As data extraction is not conducted, all of examples are not available at this stage. In this case, it marked as N/A.
*** Benefits/challenges of the use of RWD are collected in outcome variables.
**** In cases where trials have more than two arms, only the arms considered as relevant for decision problem in evidence submission are included. If there are two intervention arms and these arms are separately used for different indications in appraisals, the data extraction is carried out separately. When two arms are relevant as comparators for same indication, the data are recorded without distinguishing these arms.
